Lumida
/PODD
⌘K
Insulet Corp

Insulet Corp

PODD
$164.06USD↓-0.23%-0.37 today

MARKET CAP

11.4B

P/E (TTM)

30.6x

FWD P/E

22.9x

DAY RANGE

$159 – $166

52W RANGE

$139
$355

AI Summary

Stalk
StalkMedium

Early Stage 1 consolidation has stabilized with repaired short-term EMAs and a Momentum Breakout cleared the recent resistance cluster, signaling new demand. However, price is now extended above the rising 9- and 21-period EMAs and is Extreme Overbought, indicating poor timing for immediate entries. We maintain a medium-term bullish bias but will await a corrective pullback into the EMA support zone before engaging.

  • ↑Q1 revenue reached $762 M (+30% YoY) driven by Omnipod demand
  • ↑International Omnipod 5 launch drove 45% overseas sales growth
  • ↓Class action alleges Omnipod safety misrepresentation, adding volatility
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Insulet Corporation (NASDAQ: PODD) is a prominent leader in the diabetes management sector, primarily known for its innovative Omnipod insulin delivery system. The company operates within a high-growth market that focuses on automated insulin delivery solutions, catering to both Type 1 and Type 2 diabetes patients. With a commitment to enhancing patient outcomes through advanced technology, Insulet is well-positioned amidst the ongoing transformation in diabetes care.

Bull says

  • ↑Q1 revenue reached $762 M (+30% YoY) driven by Omnipod demand
  • ↑International Omnipod 5 launch drove 45% overseas sales growth
  • ↑Global customer base +25% YoY; U.S. Omnipod revenue +28%
  • ↑R&D investments underpin Omnipod 6 pipeline and product innovation
  • ↑Repurchased 1.25 M shares for $300 M, showcasing capital discipline
  • ↑High growth and quality factors; rising institutional ownership signals confidence

Bear says

  • ↓Class action alleges Omnipod safety misrepresentation, adding volatility
  • ↓Negative earnings yield signals underwhelming return potential
  • ↓Analyst EPS revisions trending down, indicating tougher revenue outlook
  • ↓Negative momentum suggests investor skepticism and stock weakness
  • ↓Type 2 customer retention slipping, elevating churn risk
  • ↓Ongoing litigation and regulatory challenges may overshadow growth

Investment themes with PODD

Medical Devices↑ +0.12%

Devices and instruments for medical treatment

ISRG · ABT · SYK
Demographics: Elderly Care↓ -0.26%

Services and products for aging population

UCB.BR · JNJ · AZN

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-10-2026neutral

Transcript signals

Bull points

  • We had about 10 million just from some inventory from that was coming in quarter one. It went actualized, so it'll come out of quarter two. But you'll see, I mean, quarter two, we have a really strong call.
  • we're pleased to report a strong start to 2026 with continued growth momentum, robust margin expansion, and disciplined execution of the strategic priorities we shared at Investor Day.
  • In the first quarter, we achieved 30% revenue growth, including 28% in the US and 45% internationally.

Bear points

  • the pace of it will moderate a little bit as we sort of anniversary some of these launches and continue the evolution of our install base from Dash to Omnipod 5.
  • We did experience greater than normal seasonality, which we believe was driven by the annual reset of deductibles impacting patient copays and coinsurance.
  • These factors contributed to what appears to be a slower start to the year across the U.S. diabetes category.
Read full transcript analysis ›